T11	Exp 225 229	that
T12	Exp 230 238	the rate
T13	Exp 257 274	the HIV-1 disease
T14	Exp 429 433	that
T15	Exp 554 559	which
T16	Exp 388 399	The authors
T17	Exp 490 509	the bioavailability
T18	Exp 610 620	this study
T19	Exp 922 938	its steady state
T20	Exp 965 981	its inactivation
T21	Exp 846 850	that
T22	Exp 1046 1048	We
T23	Exp 1059 1063	that
T24	Exp 1227 1229	We
T25	Exp 1239 1243	that
T26	Exp 1386 1405	the HIV-1 infection
T27	Exp 1330 1344	This mechanism
R4	Coref Anaphora:T15 Antecedent:T3
R5	Coref Anaphora:T19 Antecedent:T5
R6	Coref Anaphora:T20 Antecedent:T5
T1	Protein 13 41	tumour necrosis factor alpha
T2	Protein 513 541	tumour necrosis factor alpha
T3	Protein 543 552	TNF-alpha
T4	Protein 633 642	TNF-alpha
T5	Protein 873 882	TNF-alpha
T6	Protein 1009 1035	TNF-alpha receptor type II
T7	Protein 1162 1171	TNF-alpha
T8	Protein 1195 1204	TNF-alpha
T9	Protein 1244 1253	TNF-alpha
